Skip to content
Aminoscope
Head-to-head

Orforglipron vs Tirzepatide

The widest efficacy gap in the incretin class set against the widest convenience gap: a dual agonist injection versus a once-daily tablet — both now approved.

By Julian RothResearch & dataUpdated October 2026

Short answer

On weight loss, tirzepatide comes out ahead, with 20.9% at 72 weeks in SURMOUNT-1 against 11.2% at 72 weeks in ATTAIN-1 for orforglipron. Those figures come from separate trials, not a head-to-head study. Both are FDA-approved. Orforglipron is taken by mouth once a day, while tirzepatide is injected once a week, so orforglipron suits someone who would rather not inject.

Orforglipron

FDA-approved

~11% in ATTAIN-1; a scalable oral pill whose appeal is access, not peak efficacy. FDA-approved for weight management (Foundayo, 2026) — the type-2 diabetes indication is still under review.

Full Orforglipron evidence review

Tirzepatide

Zepbound / Mounjaro

FDA-approved

Up to ~21% mean weight loss in SURMOUNT-1 — the most effective FDA-approved weight-management drug.

Full Tirzepatide evidence review

Orforglipron vs Tirzepatide: head to head

FDA status / approved use

Orforglipron

FDA-approved April 2026 as Foundayo for chronic weight management; diabetes indication still under review

Tirzepatide

Prescription drug sold as Mounjaro and Zepbound
Marketed for

Orforglipron

Weight loss, type-2 diabetes

Tirzepatide

Weight loss, type-2 diabetes
Outcome areas

Orforglipron

Weight loss / appetite; Blood sugar / insulin sensitivity

Tirzepatide

Weight loss / appetite; Blood sugar / insulin sensitivity
Evidence grade

Orforglipron

FDA-approved

Tirzepatide

FDA-approved
How it works

Orforglipron

Small-molecule, non-peptide GLP-1 receptor agonist that survives digestion

Tirzepatide

Dual agonist of the GLP-1 and GIP receptors
Route and dosing

Orforglipron

Oral tablet, once daily (Foundayo label); maintenance 5.5 mg or higher once daily, by response and tolerability

Tirzepatide

Subcutaneous, once weekly (Zepbound label); maintenance 5, 10 or 15 mg once weekly (10 or 15 mg for sleep apnea)
Headline human result

Orforglipron

11.2% mean weight loss vs 2.1% on placebo at 72 weeks (ATTAIN-1, 36 mg daily)

Tirzepatide

20.9% mean weight loss vs 3.1% on placebo at 72 weeks (SURMOUNT-1, 15 mg weekly)
Strongest evidence

Orforglipron

ATTAIN-1, NEJM 2025Orforglipron evidence reviewPubMed 40960239

Tirzepatide

SURMOUNT-1, NEJM 2022Tirzepatide evidence reviewPubMed 35658024
Key safety signal

Orforglipron

Dose-related nausea, vomiting and diarrhea; no long-term cardiovascular or renal outcomes trial yet

Tirzepatide

Gastrointestinal side effects, the same class as semaglutide
How it is obtained

Orforglipron

Prescription drug

Tirzepatide

Prescription. Manufacturer self-pay for Zepbound runs $299–$449 per fill, against a $1,086 list priceZepbound cost breakdown

marks a row where the two differ. “Not established” marks a cell the available evidence does not answer. Evidence grades come from our evidence matrix, which grades each molecule on the human data for the use it is marketed for.

FDA-approved:
Approved by the FDA for a defined indication, on the strength of pivotal human trials.

Our verdict

Tirzepatide is the more effective drug: SURMOUNT-1 reported mean reductions up to roughly 20.9%, and SURMOUNT-5 beat semaglutide in a genuine head-to-head. Orforglipron reported about 11% in ATTAIN-1, and since its 2026 FDA approval for weight management it is a real prescribing option rather than a pipeline entry. The two have never been compared directly, so the numbers sit in separate trials with different populations and durations. Read side by side, this is a straight trade between peak efficacy and a scalable pill — and both sides of that trade now exist as treatments.

Orforglipron fits if

You want the convenience of an ordinary daily tablet — no injection, no food or water timing — and roughly half the peak weight loss is an acceptable price.

Tirzepatide fits if

You want the largest average weight loss the approved options currently support and can accept a weekly injection.

Orforglipron vs Tirzepatide: common questions

Are orforglipron and tirzepatide both FDA-approved?
Yes. Orforglipron was FDA-approved in April 2026 as Foundayo for chronic weight management; diabetes indication still under review. Tirzepatide is a prescription drug sold as Mounjaro and Zepbound.
Which has stronger human evidence, orforglipron or tirzepatide?
Neither clearly. Both have approval-level evidence. The key source for orforglipron is ATTAIN-1, NEJM 2025; for tirzepatide, it is SURMOUNT-1, NEJM 2022.
What are the main safety concerns with orforglipron and tirzepatide?
For orforglipron, watch for dose-related nausea, vomiting and diarrhea; no long-term cardiovascular or renal outcomes trial yet. For tirzepatide, watch for gastrointestinal side effects, the same class as semaglutide.

Key studies behind each

Orforglipron

  1. Frias JP, Hsia S, Eyde S, et al. (2023). Efficacy and safety of oral orforglipron in patients with type 2 diabetes: a multicentre, randomised, dose-response, phase 2 study. Lancet. PubMed 37369232
  2. Wharton S, et al. (2025). Treatment with orforglipron, an oral glucagon-like peptide-1 receptor agonist, is associated with cardiometabolic improvements. Cardiovasc Diabetol. PubMed 40481478
  3. Rosenstock J, Frias JP, Rodbard HW, et al. (2025). Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist, in Early Type 2 Diabetes. N Engl J Med. PubMed 40544435
  4. Wharton S, Aronne LJ, Wadden TA, et al. (2025). Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment. N Engl J Med. PubMed 40960239

Tirzepatide

  1. Wilding JPH, Batterham RL, Calanna S, et al. (2021). Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1). N Engl J Med. PubMed 33567185
  2. Jastreboff AM, Aronne LJ, Ahmad NN, et al. (2022). Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1). N Engl J Med. PubMed 35658024
  3. Frías JP, Davies MJ, Rosenstock J, et al. (2021). Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes (SURPASS-2). N Engl J Med. PubMed 34170647
  4. Aronne LJ, Horn DB, le Roux CW, et al. (2025). Tirzepatide as Compared with Semaglutide for the Treatment of Obesity (SURMOUNT-5). N Engl J Med. PubMed 40353578

The full evidence reviews

Related comparisons